Merck & Co., Inc. (MRK)

In the past six months, Merck's stock has experienced several notable events and movements. Merck reported its Q4 2025 earnings, beating analysts' estimates, and announced its Q1 2026 earnings call. Merck announced its intent to acquire Terns Pharmaceuticals and expanded its pipeline through an exclusive license agreement with Hengrui Pharma. Several firms upgraded Merck's stock, and Merck increased its dividend to $0.85 in December 2025. Merck shares hit a 4-week high of $121.53 in March 2026, but also experienced a 6-week low of $113.34 earlier that month.

Merck's products and services exhibit some demand seasonality, particularly for vaccines and certain new product launches. Merck's stock has historically shown a strong seasonal pattern between April 1st and June 30th. The company reported solid seasonal uptake in adult pneumococcal vaccination in Q4 2025. In Q1 2025, there was higher demand for certain products in the U.S., while some international markets experienced lower demand due to generic competition. Sales of Animal Health products also saw growth primarily due to higher demand for livestock products. Conversely, Gardasil/Gardasil 9 sales declined in Q1 2025, and demand for some products in the Asia Pacific region, particularly Japan, also saw a decline.

Merck & Co., Inc. is a global healthcare company operating in the pharmaceutical sector, focusing on discovering, developing, manufacturing, and marketing prescription medicines, vaccines, biologic therapies, and animal health products. Key products include Keytruda, Gardasil, and a broad portfolio of animal health products, along with other human health pharmaceuticals for infectious diseases, cardiovascular diseases, and diabetes.

Merck & Co., Inc. operates globally with a significant presence across seven regions: the United States; Europe, Middle East and Africa (EMEA); Latin America; Asia Pacific (excluding China and Japan); Japan; China; and Other regions. The United States is the largest contributor to Merck's total revenue.

Merck has a long-standing reputation as a global biopharmaceutical company focused on research and development. However, its brand reputation has faced challenges due to the Gardasil litigation controversy and historical controversies like the Vioxx scandal.

Merck & Co., Inc. has a significant institutional ownership, with 79.70% of its stock held by institutional shareholders, 20.08% by individual investors, and 0.22% by insiders. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., and State Street Corp.